NCT06975631View on ClinicalTrials.gov

Post-market Study on TrHCROSS® in Knee Osteoarthritis After a Single Injection

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

August 10, 2023

Study Completion Date

February 14, 2024

Conditions
Knee Osteoarthritis
Interventions
DEVICE

TrHCROSS®

Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked.

DEVICE

Hyalone®

Single injection of 4.4 ml of viscoelastic sodium hyaluronate solution crosslinked

Trial Locations (1)

01009

University Hospital of Álava, Vitoria-Gasteiz

Sponsors

Collaborators (1)

Bioaraba
All Listed Sponsors
collaborator

Hospital Universitario Araba

OTHER

collaborator

Bioaraba

UNKNOWN

lead

i+Med S.Coop.

INDUSTRY

NCT06975631 - Post-market Study on TrHCROSS® in Knee Osteoarthritis After a Single Injection | Biotech Hunter | Biotech Hunter